title: Non-antibiotic treatments for bacterial diseases in an era of progressive antibiotic resistance.
abstract: The emergence of multi-drug resistant (MDR) microbial pathogens threatens the very foundation upon which standard antibacterial chemotherapy is based. We must consider non-antibiotic solutions to manage invasive bacterial infections. Transition from antibiotics to non-traditional treatments poses real clinical challenges that will not be easy to solve. Antibiotics will continue to reliably treat some infections (e.g., group A streptococci and Treponema pallidum) but will likely need adjuvant therapies or will need to be replaced for many bacterial infections in the future.
authors.affiliation: Infectious Disease Division, Alpert Medical School of Brown University, Providence, RI, USA. Steven_Opal@brown.edu.|Ocean State Clinical Coordinating Center, 1 Virginia Ave, Suite 105, Providence, RI, 02905, USA. Steven_Opal@brown.edu.
authors.forename: Steven M
authors.initials: SM
authors.lastname: Opal
mesh_terms: D001424:Bacterial Infections / Q000628:therapy*; D001435:Bacteriophages / Q000472:pathogenicity; D024881:Drug Resistance, Bacterial; D006440:Hemofiltration / Q000379:methods / Q000592:standards; D006801:Humans; D000071059:Phage Therapy / Q000592:standards; D053038:Quorum Sensing; D013812:Therapeutics / Q000379:methods* / Q000592:standards*
keywords: Antibiotic resistance; Monoclonal antibodies to treat bacterial infections; Novel therapies for bacterial infections; Phage therapy; Quorum-sensing inhibitors